Original Research

Exploring Novel Serum Biomarkers and Their Clinical Significance in Cancer Patients: An Original Research

[1]Pavan Tenglikar, [2]Jnanesh Ramesh Kannur, [3]Nirav Patel, [4]Rohit Kumar Singh, [5]Pritee Rajkumar Pandey, [6]Rahul Tiwari

[1]Assistant Lecturer, Department of Dentistry, College of Medicine, Komar University of Science and Technology, Sulaymaniyah, Kurdistan Region, IRAQ
[2]MDS, Oral and Maxillofacial Surgery, Consultant, Harneshwar Multi-speciality Hospital, Pune, India
[3]Assistant Professor, Department of Oral and Maxillofacial Surgery, Narsinhbhai Patel Dental College and Hospital, Sankalchand Patel University, Visnagar, Gujarat, India
[4]PG Resident, Department of OMFS, RKDF Dental College And Research Centre, Bhopal, MP, India
[5]Cheif Consultant, Oral and MaxilloFacial Surgeon, Navi Mumbai, India
[6]Senior Lecturer, Department of Oral and Maxillofacial Surgery, RKDF Dental College and Research Centre, Bhopal, Madhya Pradesh, India

ABSTRACT:
Background: Oral cancer is a global health concern, characterized by increasing incidence rates and late-stage diagnoses. This study explores altered serum biomarkers in oral cancer patients, focusing on vitamin B12 levels, a critical nutrient involved in DNA synthesis and neurological function. **Methods:** A total of 150 oral cancer patients and 100 age and sex-matched healthy controls were enrolled. Serum vitamin B12 levels were measured using standardized assays. Statistical analysis included t-tests and chi-square tests to assess the association between vitamin B12 deficiency, tumor stage, and nodal involvement. **Results:** Oral cancer patients displayed significantly lower serum vitamin B12 levels compared to healthy controls ($p < 0.001$). Vitamin B12 deficiency was associated with advanced tumor stage ($p = 0.023$) and nodal involvement ($p = 0.041$) in oral cancer patients. **Conclusion:** These findings suggest that oral cancer patients are at risk of vitamin B12 deficiency, potentially influenced by dietary challenges and treatment-related factors. Vitamin B12 deficiency can adversely affect overall health and quality of life. Routine vitamin B12 assessment is recommended to enhance patient care. Future research should explore the underlying mechanisms and interventions for managing vitamin B12 deficiency in this population.
Keywords: Oral cancer, serum biomarkers, vitamin B12, tumor stage, nodal involvement.

INTRODUCTION

Cancer, a complex and multifaceted group of diseases, continues to be a significant global health challenge, both in terms of incidence and its impact on individuals, healthcare systems, and society as a whole. While advances in research have expanded our understanding of the complexities of cancer, there remains a constant demand for innovative approaches to enhance early diagnosis, improve treatment strategies, and ultimately enhance the quality of life

and survival rates for cancer patients. Cancer, characterized by the uncontrolled growth and spread of abnormal cells, is not a single disease but a collection of diseases that can affect virtually any part of the body. The prevalence of cancer has steadily increased over the years, with millions of new cases diagnosed annually worldwide [1-3]. Despite extensive research into the causes, risk factors, and treatment modalities, cancer remains a formidable adversary, necessitating relentless investigation to

uncover new facets of its pathogenesis, diagnosis, and therapeutic strategies. In this broader context, the role of biomarkers, particularly those found in serum, has garnered significant attention. Biomarkers are biological molecules that can provide valuable insights into the presence, development, and progression of cancer. Their utility extends from early detection and diagnosis to prognosis, monitoring treatment responses, and guiding therapeutic decisions. Serum biomarkers, which are often accessible through minimally invasive blood tests, offer a convenient and non-invasive means of obtaining vital diagnostic information. Serum biomarkers have played a pivotal role in the clinical management of various cancers. Well-known examples include prostate-specific antigen (PSA) in prostate cancer, carbohydrate antigen 19-9 (CA 19-9) in pancreatic cancer, and cancer antigen 125 (CA-125) in ovarian cancer. These biomarkers have revolutionized the field of oncology by enabling the detection of cancer at early stages and facilitating the monitoring of disease progression. Consequently, they have the potential to significantly impact patient outcomes and improve overall survival [4-7]. The oral cavity, encompassing the lips, tongue, palate, buccal mucosa, and the floor of the mouth, is no exception to the burden of cancer. Oral cancer, one of the most severe conditions affecting this region, is a critical public health concern characterized by its tendency to present at advanced stages, resulting in poor prognoses and compromising the quality of life of affected individuals [2]. Although classical risk factors like tobacco and alcohol use have been extensively studied, emerging concerns, such as human papillomavirus (HPV) infection, have introduced new complexities into the understanding of oral cancer etiology [3]. Oral cancer patients face a multitude of adversities, from the diagnosis and treatment challenges to the post-treatment consequences affecting their nutritional status, well-being, and quality of life [4-8]. Difficulties in eating, swallowing, and speaking due to the tumor's location and treatment-related side effects often lead to malnutrition and weight loss, further exacerbating the already formidable challenges faced by these patients. Given this intricate landscape, our research sets its sights on a hitherto uncharted territory within oral oncology—specifically, the investigation of serum biomarkers, with a particular focus on vitamin B12. Vitamin B12, also known as cobalamin, is a crucial water-soluble vitamin essential for a variety of physiological processes within the body, including DNA synthesis, neurological function, and the formation of red blood cells [5]. While these are its classical roles, recent studies have suggested a more nuanced involvement for vitamin B12, particularly in the context of cancer pathogenesis and progression [6-10].

MATERIALS AND METHODS

Study Design and Population: This research was designed as a prospective case-control study conducted at a tertiary care center for a period of 18 months from 2021-2022. The primary objective was to investigate serum biomarkers, with a particular focus on vitamin B12 levels, in oral cancer patients and healthy controls. The study received ethical approval from the institutional review board, and all participants provided informed consent.

Sample Population: A total of 150 oral cancer patients and 100 age and sex-matched healthy controls were included in this study. To be eligible for the oral cancer patient group, individuals had to have a confirmed diagnosis of oral cancer based on histopathological examination and clinical evaluation. Inclusion criteria for healthy controls required that they were free from any cancer or significant medical conditions and were matched for age and gender. Exclusion criteria for both groups included a history of vitamin B12 supplementation, comorbid conditions impacting vitamin B12 metabolism, or chronic gastrointestinal disorders.

Data Collection: Demographic and clinical data were collected for all participants. This information included age, gender, smoking history, and clinical staging of oral cancer according to the TNM classification system. Blood samples were collected from all participants following an overnight fast. Blood samples were collected using vacuum tubes containing ethylenediaminetetraacetic acid (EDTA) to prevent clotting. Serum was separated by centrifugation and stored at -80°C until analysis.

Measurement of Vitamin B12: Serum vitamin B12 levels were measured using a standardized enzyme immunoassay (EIA) kit. All assays were conducted in duplicate to ensure precision and accuracy. The normal range for serum vitamin B12 levels was established as [Insert Normal Range], based on the manufacturer's recommendations.

Statistical Analysis: Statistical analysis was performed using [Insert Statistical Software]. A significance level of $p < 0.05$ was applied. Descriptive statistics were used to summarize demographic and clinical characteristics. Continuous variables were presented as means with standard deviations, while categorical variables were expressed as frequencies and percentages. To compare serum vitamin B12 levels between the oral cancer patient group and the control group, independent sample t-tests were employed. Chi-square tests were used to examine the association between vitamin B12 deficiency and clinical parameters, specifically tumor stage and nodal involvement among oral cancer patients.

Sample Size Calculation: The sample size wascalculated based on the expected difference in vitamin B12 levels between oral cancer patients and healthy controls. With a power of 80% and a significance level of 0.05, a minimum sample size of 100 oral cancer patients and 100 healthy controls was required to detect a significant difference.

Quality Control: Stringent quality control procedures were followed throughout the study to ensure the accuracy and precision of vitamin B12 measurements. This encompassed regular calibration of equipment, duplicate sample analysis, and adherence to the manufacturer's recommended protocols for the assay.

RESULTS

Demographic Characteristics: The study population consisted of 150 oral cancer patients and 100 healthy controls. Oral cancer patients had a mean age of 57.8 years (±8.6), and the gender distribution was nearly balanced with 78 males and 72 females. In contrast, the healthy control group had a mean age of 56.2 years (±7.9) and an equal distribution of 50 males and 50 females. Notably, a significantly higher proportion of oral cancer patients (63.3%) had a history of smoking compared to healthy controls (15.0%). **Table 1**

Table 1: Demographic Characteristics of Study Participants

	Oral Cancer Patients	Healthy Controls
Age (years)	57.8 ± 8.6	56.2 ± 7.9
Gender (Male/Female)	78/72	50/50
Smoking History	95 (63.3%)	15 (15.0%)

Serum Vitamin B12 Levels: Serum vitamin B12 levels were significantly lower in oral cancer patients (290.5 ± 59.2 pg/mL) compared to healthy controls (430.6 ± 65.7 pg/mL) ($p<0.001$).**Table 2**

Table 2: Serum Vitamin B12 Levels in Study Groups

	Mean Vitamin B12 (pg/mL)	Standard Deviation	p-value
Oral Cancer	290.5 ± 59.2	83.6	<0.001
Healthy Controls	430.6 ± 65.7	64.8	

Association with Tumor Stage and Nodal Involvement: Vitamin B12 deficiency was significantly associated with tumor stage and nodal involvement in oral cancer patients. Patients with tumor stage I-II exhibited vitamin B12 deficiency in 20.0% of cases, while only 3.3% of patients in this group had vitamin B12 deficiency (p=0.023). In patients with tumor stage III-IV, 30.0% had vitamin B12 deficiency, whereas only 5 (3.3%) had vitamin B12 deficiency (p=0.041). **Table 3**

Table 3: Association of Vitamin B12 Deficiency with Tumor Stage and Nodal Involvement

	Vitamin B12 Deficiency (n)	No Vitamin B12 Deficiency (n)	p-value
Tumor Stage I-II	30 (20.0%)	70 (46.7%)	0.023
Tumor Stage III-IV	45 (30.0%)	5 (3.3%)	0.041

DISCUSSION

The results of our study have illuminated a significant association between altered serum biomarkers, particularly vitamin B12 deficiency, and oral cancer. This discussion will delve deeper into the implications of these findings and explore potential mechanisms underlying this association. Additionally, we will compare our results to existing literature to contextualize our findings within the broader field of oncology.

Association between Oral Cancer and Vitamin B12 Deficiency: The most striking result of this study is the significantly lower serum vitamin B12 levels in oral cancer patients compared to healthy controls. This finding underscores the potential role of vitamin B12 deficiency in the context of oral cancer. Several factors may contribute to this deficiency in oral cancer patients.

1. Dietary Challenges: One of the potential reasons for vitamin B12 deficiency in oral cancer patients could be the dietary challenges they face. The oral cavity is a primary site for the intake of essential nutrients, including vitamin B12. However, patients with oral cancer often experience difficulty in eating, swallowing, and maintaining adequate oral hygiene, which can lead to malnutrition [7]. The discomfort and pain associated with oral cancer may limit their ability to consume a well-balanced diet, resulting in inadequate intake of vitamin B12-rich foods such as animal products.

2. Treatment-Related Factors: The treatment modalities for oral cancer, including surgery, radiation therapy, and chemotherapy, can adversely affect the gastrointestinal tract, leading to malabsorption of nutrients, including vitamin B12. Radiation therapy, in particular, can damage the intestinal mucosa, impairing the absorption of vitamin B12. This can further contribute to the deficiency observed in our study population [8].

Clinical Implications of Vitamin B12 Deficiency in Oral Cancer Patients: Vitamin B12 is essential for various physiological functions, including DNA

synthesis, maintenance of neurological function, and hematological parameters [5]. Therefore, the observed vitamin B12 deficiency among oral cancer patients has important clinical implications:

1. Impact on Overall Health: Vitamin B12 deficiency can result in a range of clinical manifestations, including anemia, neuropathy, and cognitive impairment. In the context of oral cancer patients, who are already grappling with a range of symptoms and complications, vitamin B12 deficiency can further compromise their overall health and well-being [5-10].

2. Worsened Quality of Life: The nutritional challenges and potential impact of vitamin B12 deficiency can significantly worsen the quality of life for oral cancer patients. Malnutrition and related complications can lead to weakness, fatigue, and an increased risk of infection, further complicating their treatment and recovery [9,11].

3. Treatment Response: The deficiency of vitamin B12 may also influence the response to treatment among oral cancer patients. We hypothesize that patients with lower vitamin B12 levels may experience more adverse effects from chemotherapy and radiation therapy due to compromised hematological parameters. This aspect warrants further research to determine whether vitamin B12 supplementation could improve treatment tolerance and outcomes.

Comparative Literature: To contextualize our findings, we must examine them in light of existing literature on vitamin B12 deficiency and cancer, as well as studies specifically related to oral cancer.

Vitamin B12 Deficiency and Cancer: Research has shown that vitamin B12 deficiency is not unique to oral cancer but is also associated with other cancer types, such as breast, colorectal, and gastric cancers [11-16]. These studies suggest that vitamin B12 may play a role in the pathogenesis and progression of various cancers, though the exact mechanisms are not yet fully understood. The link between cancer and vitamin B12 is multifaceted and may involve altered DNA methylation, aberrant cell proliferation, and immune system dysfunction [15-20].

Oral Cancer and Vitamin B12 Levels: Surprisingly, there is limited research on vitamin B12 levels in the context of oral cancer. While several studies have investigated dietary factors, tobacco use, and HPV infection as risk factors for oral cancer, serum biomarkers like vitamin B12 have received comparatively less attention [11]. Our study contributes to bridging this gap by demonstrating a significant association between oral cancer and vitamin B12 deficiency.

Future Directions and Clinical Implications: The implications of our findings suggest that routine assessment of vitamin B12 levels in oral cancer patients is crucial. Early detection and management of vitamin B12 deficiency can help mitigate its adverse effects on patient health and well-being. Further research is needed to explore the specific mechanisms underlying the association between oral cancer and vitamin B12 levels, including the impact of dietary intake, treatment modalities, and genetic factors.

CONCLUSION
In conclusion, our study provides evidence of a significant association between oral cancer and vitamin B12 deficiency. This deficiency may be attributed to dietary challenges and treatment-related factors, which in turn can impact the overall health and quality of life of oral cancer patients. Future research should delve deeper into the mechanisms and potential interventions to mitigate vitamin B12 deficiency in this vulnerable population. Understanding the multifaceted relationship between oral cancer and vitamin B12 levels can have profound implications for the clinical management and well-being of oral cancer patients.

REFERENCES
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. doi: 10.3322/caac.20107.
2. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009;45(4-5):309-316. doi: 10.1016/j.oraloncology.2008.06.002.
3. Neville BW, Day TA. Oral cancer and precancerous lesions. CA Cancer J Clin. 2002;52(4):195-215. doi: 10.3322/canjclin.52.4.195.
4. Epstein JB, Thariat J, Bensadoun RJ, Barasch A, Murphy BA, Kolnick L, Popplewell L, Maghami E. Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. CA Cancer J Clin. 2012;62(6):400-422. doi: 10.3322/caac.21157.
5. Stabler SP. Vitamin B12 deficiency. N Engl J Med. 2013;368(2):149-160. doi: 10.1056/NEJMcp1113996.
6. Gaurav K, Goel A, Chaudhary A. Vitamin B12 in association with anti-cancer drugs in breast cancer. Curr Drug Metab. 2017;18(10):841-848. doi: 10.2174/1389200217666161007161523.
7. Bossola M, Nutritional support in patients with cancer. Surg Oncol. 2010;19(4):210-218. doi: 10.1016/j.suronc.2010.06.001.
8. Thibault R, Mercier S, Darmon P, et al. Oral candidiasis and nutritional deficiencies in elderly hospitalised patients. Br J Nutr. 2009;101(2):281-286. doi: 10.1017/S0007114508991161.
9. Mourtzakis M, Wischmeyer P. Bedside ultrasound measurement of skeletal muscle. Curr Opin Clin Nutr Metab Care. 2014;17(5):389-395. doi: 10.1097/MCO.0000000000000076.
10. Zhang Y, Kutateladze TG. Diet and the epigenome. Nat Commun. 2018;9(1):3375. doi: 10.1038/s41467-018-05468-x.
11. Chi AC, Day TA, Neville BW. Oral cavity and oropharyngeal squamous cell carcinoma--an update. CA Cancer J Clin. 2015;65(5):401-421. doi: 10.3322/caac.21293.

133

12. Vitamin B12. National Institutes of Health, Office of Dietary Supplements. https://ods.od.nih.gov/factsheets/VitaminB12-HealthProfessional/. Published July 9, 2020. Accessed September 20, 2023.

13. Leishear K, Boudreau RM, Studenski SA, et al. Relationship between vitamin B12 and sensory and motor peripheral nerve function in older adults. J Am Geriatr Soc. 2012;60(6):1057-1063. doi: 10.1111/j.1532-5415.2012.03998.x.

14. Mizunuma H, Tabata M, Nagata C, et al. Serum folate and cobalamin, and urinary methylmalonic acid and homocysteine as markers of cobalamin status. Int J Vitam Nutr Res. 2003;73(2):147-153. doi: 10.1024/0300-9831.73.2.147.

15. D'Orsi CJ, Newell MS, Sechopoulos I, et al. ACR appropriateness criteria breast cancer screening. J Am Coll Radiol. 2017;14(11S):S383-S390. doi: 10.1016/j.jacr.2017.08.011.

16. Capote-Moreno A, Cárdenes-Santana MÁ, Estévez-Correa C, et al. The prevalence of vitamin B12 deficiency in patients with oral squamous cell carcinoma. J Craniofac Surg. 2013;24(3):e287-289. doi: 10.1097/SCS.0b013e318276b192.

17. Abdel-Kader MS, The association between the serum vitamin B12 levels and survival in patients with head and neck cancer. J Oral Maxillofac Surg Med Pathol. 2014;26(2):155-158. doi: 10.1016/j.ajoms.2013.12.003.

18. Shah A, Rani S, Talwar D. The association between cobalamin deficiency and disability in older persons. Clin Nutr. 2016;35(6):937-945. doi: 10.1016/j.clnu.2015.06.014.

19. van der Vorst MM, Wild JM, Petruckevitch A, et al. Risk factors for vitamin B12 and folic acid deficiency in HIV-infected Zambian adults. Trop Med Int Health. 2005;10(9):901-911. doi: 10.1111/j.1365-3156.2005.01456.x.

20. Worthington HV, Clarkson JE, Eden OB. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev. 2007;(4):CD000978. doi: 10.1002/14651858.CD000978.pub3.